Sorafenib is a multi-targeted receptor tyrosine kinase inhibitor (TKI), with activity against vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, Raf-1, B-Raf, C-Raf, and plateletderived growth factor receptor (PDGFR) -α and -β. Currently, sorafenib has regulatory approval for use in metastatic renal cell carcinoma and hepatocellular carcinoma. An attractive activity profile, pre-clinical evidence of antitumor activity in human malignant glioma models and a promising safety profile have led to recent phase I/II clinical trials for patients with malignant gliomas. Here we review the current data, and future directions for the development of sorafenib for malignant glioma.
